

Thierry Calandra

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8641605/thierry-calandra-publications-by-citations.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194
papers

38,720
citations

75
h-index

196
g-index

211
ext. papers

43,353
ext. citations

10.2
avg, IF

6.8
L-index

#	Paper	IF	Citations
194	Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. <i>Critical Care Medicine</i> , 2008 , 36, 296-327	1.4	6589
193	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Critical Care Medicine</i> , 2004 , 32, 858-73	1.4	4049
192	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1813-21	11.6	3744
191	Macrophage migration inhibitory factor: a regulator of innate immunity. <i>Nature Reviews Immunology</i> , 2003 , 3, 791-800	36.5	1780
190	2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. <i>Clinical Infectious Diseases</i> , 2002 , 34, 730-51	11.6	1515
189	Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. <i>Intensive Care Medicine</i> , 2008 , 34, 17-60	14.5	1302
188	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Intensive Care Medicine</i> , 2004 , 30, 536-55	14.5	1144
187	MIF as a glucocorticoid-induced modulator of cytokine production. <i>Nature</i> , 1995 , 377, 68-71	50.4	1004
186	Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. <i>Clinical Infectious Diseases</i> , 2008 , 46, 201-11	11.6	707
185	Protection from septic shock by neutralization of macrophage migration inhibitory factor. <i>Nature Medicine</i> , 2000 , 6, 164-70	50.5	650
184	Sepsis: a roadmap for future research. <i>Lancet Infectious Diseases</i> , 2015 , 15, 581-614	25.5	616
183	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
182	The international sepsis forum consensus conference on definitions of infection in the intensive care unit. <i>Critical Care Medicine</i> , 2005 , 33, 1538-48	1.4	585
181	High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. <i>American Journal of Medicine</i> , 1991 , 91, 23-9	2.4	519
180	Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. <i>Nature</i> , 2000 , 408, 211-6	50.4	484
179	MIF regulates innate immune responses through modulation of Toll-like receptor 4. <i>Nature</i> , 2001 , 414, 920-4	50.4	463
178	Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). <i>Biochemistry</i> , 1994 , 33, 14144-55	3.2	368

177	Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. <i>Critical Care Medicine</i> , 1999 , 27, 1066-72	1.4	352
176	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017 , 102, 433-444	6.6	323
175	Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. <i>New England Journal of Medicine</i> , 1987 , 317, 1692-8	59.2	323
174	Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. <i>Clinical Infectious Diseases</i> , 2004 , 38, 311-20	11.6	322
173	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. <i>Clinical Infectious Diseases</i> , 2008 , 47, 674-83	11.6	308
172	Dominant TNF- α Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011 , 17, 372-6	50.5	304
171	Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. <i>New England Journal of Medicine</i> , 1999 , 341, 312-8	59.2	303
170	Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. <i>Microbes and Infection</i> , 2002 , 4, 449-60	9.3	283
169	Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. <i>PLoS Pathogens</i> , 2009 , 5, e1000480	7.6	250
168	Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. <i>Blood</i> , 2011 , 117, 1205-17	2.2	244
167	Bacteremia due to viridans streptococci in neutropenic patients: a review. <i>American Journal of Medicine</i> , 1994 , 97, 256-64	2.4	238
166	1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. <i>Clinical Infectious Diseases</i> , 2008 , 46, 878-85	11.6	219
165	Changes in the epidemiological landscape of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i4-i13	5.1	208
164	Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2348-52	11.5	201
163	The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. <i>Molecular Endocrinology</i> , 2007 , 21, 1267-80		199
162	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. <i>Critical Care</i> , 2010 , 14, R222	10.8	198
161	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3020-9		184
160	Invasive candidiasis as a cause of sepsis in the critically ill patient. <i>Virulence</i> , 2014 , 5, 161-9	4.7	181

159	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1109-16	16.6	179
158	Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia: a prospective observational study. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1101-7	11.6	172
157	Clinical significance of Candida isolated from peritoneum in surgical patients. <i>Lancet, The</i> , 1989 , 2, 1437-40		164
156	Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. <i>New England Journal of Medicine</i> , 1994 , 330, 1240-1	59.2	163
155	Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. <i>European Journal of Immunology</i> , 2005 , 35, 3405-13	6.1	161
154	Localization of Macrophage Migration Inhibitory Factor (MIF) to Secretory Granules within the Corticotrophic and Thyrotrophic Cells of the Pituitary Gland. <i>Molecular Medicine</i> , 1995 , 1, 781-788	6.2	158
153	Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. <i>Cellular Signalling</i> , 2006 , 18, 688-703	4.9	157
152	Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. <i>Clinical Infectious Diseases</i> , 2012 , 55, 381-90	11.6	154
151	β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1100-9	10.2	151
150	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020 , 46, 1524-1535	14.5	149
149	Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock. <i>Thrombosis and Haemostasis</i> , 1989 , 61, 459-462	7	149
148	Pathogenesis of sepsis: new concepts and implications for future treatment. <i>BMJ, The</i> , 2003 , 326, 262-6	5.9	147
147	Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. <i>Critical Reviews in Immunology</i> , 1997 , 17, 77-88	1.8	146
146	Bench-to-bedside review: Candida infections in the intensive care unit. <i>Critical Care</i> , 2008 , 12, 204	10.8	145
145	Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. <i>Biochemistry</i> , 1997 , 36, 15356-62	3.2	138
144	New strategies for clinical trials in patients with sepsis and septic shock. <i>Critical Care Medicine</i> , 2001 , 29, 880-6	1.4	137
143	Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. <i>Journal of Molecular Medicine</i> , 1998 , 76, 151-61	5.5	132
142	Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. <i>Critical Care Medicine</i> , 2004 , 32, S495-512	1.4	130

141	Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. <i>Critical Care Medicine</i> , 2009 , 37, 2929-38	1.4	123
140	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. <i>Aids</i> , 2007 , 21, 441-5	6.5	122
139	Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. <i>Critical Care Medicine</i> , 2005 , 33, 1708-16	1.4	114
138	The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1291-300	15.9	103
137	Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. <i>Infection and Immunity</i> , 2000 , 68, 2259-67	3.7	102
136	Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5303-15	5.9	97
135	Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2011 , 52, 248-56	11.6	96
134	Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. <i>Clinical Infectious Diseases</i> , 2005 , 41 Suppl 7, S513-9	11.6	96
133	Antibiotics in sepsis. <i>Intensive Care Medicine</i> , 2001 , 27 Suppl 1, S33-48	14.5	96
132	Sepsis studies need new direction. <i>Lancet Infectious Diseases</i> , 2012 , 12, 503-5	25.5	94
131	Sepsis: time to reconsider the concept. <i>Critical Care Medicine</i> , 2008 , 36, 964-6	1.4	93
130	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017 , 43, 1225-1238	14.5	90
129	Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?. <i>Intensive Care Medicine</i> , 2014 , 40, 1241-55	14.5	90
128	Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. <i>Journal of Biological Chemistry</i> , 2007 , 282, 29910-8	5.4	87
127	Antibiotics for Sepsis-Finding the Equilibrium. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1433-1434	27.4	87
126	Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 137-43	5.9	86
125	Molecular basis of host-pathogen interaction in septic shock. <i>Current Opinion in Microbiology</i> , 1998 , 1, 49-55	7.9	85
124	Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. <i>Journal of Immunology</i> , 2001 , 167, 2759-65	5.3	84

123	Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1321-8	11.6	83
122	Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 51, 95-101	2.9	79
121	Fully human anti-macrophage migration inhibitory factor antibodies as potential therapeutics for sepsis and septic shock. <i>Critical Care</i> , 2008 , 12, P15	10.8	78
120	Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. <i>Infection and Immunity</i> , 2011 , 79, 2690-8	3.7	77
119	Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. <i>Biochemical Journal</i> , 2005 , 387, 355-65	3.8	71
118	Innate immunogenetics: a tool for exploring new frontiers of host defence. <i>Lancet Infectious Diseases</i> , 2007 , 7, 531-42	25.5	70
117	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016 , 20, 133	10.8	70
116	Early diagnosis of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, i19-i28	5.1	69
115	Macrophage migration inhibitory factor and host innate immune responses to microbes. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 35, 573-6		68
114	Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. <i>Journal of Biological Chemistry</i> , 2010 , 285, 26581-98	5.4	67
113	Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2017 , 25, 108	3.6	64
112	Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. <i>Journal of Clinical Oncology</i> , 2012 , 31, 1448-54	2.2	63
111	Histone deacetylase inhibitors impair antibacterial defenses of macrophages. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1367-74	7	63
110	Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. <i>Journal of Infectious Diseases</i> , 2003 , 187 Suppl 2, S385-90	7	62
109	A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. <i>PLoS ONE</i> , 2011 , 6, e24244	3.7	62
108	Bloodstream and endovascular infections due to <i>Abiotrophia defectiva</i> and <i>Granulicatella</i> species. <i>BMC Infectious Diseases</i> , 2006 , 6, 9	4	61
107	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016 , 20, 125	10.8	57
106	Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to <i>Klebsiella pneumoniae</i> sepsis. <i>Journal of Infectious Diseases</i> , 2013 , 207, 331-9	7	56

105	Macrophage migration inhibitory factor and innate immune responses to bacterial infections. <i>Critical Care Medicine</i> , 2001 , 29, S13-5	1.4	55
104	Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. <i>European Journal of Immunology</i> , 2013 , 43, 939-48	6.1	52
103	Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. <i>Intensive Care Medicine</i> , 2009 , 35, 903-8	14.5	52
102	Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3',5'-phosphate responsive element-binding protein CREB in pituitary cells. <i>Molecular Endocrinology</i> , 1998 , 12, 698-705		49
101	Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. <i>European Journal of Immunology</i> , 2007 , 37, 3509-21	6.1	48
100	Understanding and Enhancing Sepsis Survivorship. Priorities for Research and Practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 972-981	10.2	47
99	A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. <i>Biochemistry</i> , 2009 , 48, 9858-70	3.2	47
98	A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. <i>FASEB Journal</i> , 2012 , 26, 907-16	0.9	46
97	Risk factors for candidemia: a prospective matched case-control study. <i>Critical Care</i> , 2020 , 24, 109	10.8	43
96	Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). <i>Journal of Endotoxin Research</i> , 2003 , 9, 119-23		43
95	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. <i>Clinical Infectious Diseases</i> , 2005 , 40, 239-45	11.6	43
94	High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E997-1005	11.5	42
93	Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the sheet structure of MIF. <i>Journal of Biological Chemistry</i> , 2012 , 287, 7446-55	5.4	42
92	Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009 , 1793, 1749-58	4.9	41
91	Empirical antifungal therapy in neutropenic cancer patients with persistent fever. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 32-42	1.6	40
90	Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 3597-602	11.5	40
89	Species-specific recognition of <i>Aspergillus fumigatus</i> by Toll-like receptor 1 and Toll-like receptor 6. <i>Journal of Infectious Diseases</i> , 2012 , 205, 944-54	7	39
88	Macrophage migration inhibitory factor reduces the growth of virulent <i>Mycobacterium tuberculosis</i> in human macrophages. <i>Infection and Immunity</i> , 2005 , 73, 3783-6	3.7	38

87	Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. <i>Trends in Microbiology</i> , 1994 , 2, 198-201	12.4	38
86	Clinical trials of antifungal prophylaxis among patients undergoing surgery. <i>Clinical Infectious Diseases</i> , 2004 , 39 Suppl 4, S185-92	11.6	36
85	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019 , 62, 310-319	5.2	36
84	Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?. <i>PLoS ONE</i> , 2011 , 6, e18886	3.7	34
83	Treatment of sepsis: past and future avenues. <i>Drugs</i> , 1999 , 57, 127-32	12.1	34
82	Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. <i>Critical Care</i> , 2012 , 16, R114	10.8	33
81	The emerging role of MIF in septic shock and infection. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1994 , 8, 123-7		33
80	Changing face of health-care associated fungal infections. <i>Current Opinion in Infectious Diseases</i> , 2005 , 18, 314-9	5.4	32
79	Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin. <i>Infection and Immunity</i> , 2001 , 69, 378-85	3.7	31
78	Infections in neutropenic cancer patients. <i>Lancet, The</i> , 2002 , 359, 723-5	4.0	31
77	A role for the endocrine and pro-inflammatory mediator MIF in the control of insulin secretion during stress. <i>Diabetes/Metabolism Research and Reviews</i> , 1999 , 15, 47-54	7.5	31
76	Antifungals in the ICU. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 610-9	5.4	30
75	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021 , 47, 819-834	14.5	30
74	Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. <i>PLoS ONE</i> , 2012 , 7, e48524	3.7	29
73	Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 137-49	5.7	28
72	Glucocorticoid-induced MIF expression by human CEM T cells. <i>Cytokine</i> , 2009 , 48, 177-85	4	28
71	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. <i>Cytokine</i> , 2006 , 36, 51-6	4	28
70	Cytokines and septic shock. <i>Diagnostic Microbiology and Infectious Disease</i> , 1990 , 13, 377-81	2.9	26

69	Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. <i>Journal of Endocrinology</i> , 2010 , 206, 297-306	4.7	25
68	Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. <i>Intensive Care Medicine</i> , 2005 , 31, 1514-21	14.5	25
67	Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and elimination. <i>Gut Pathogens</i> , 2017 , 9, 9	5.4	24
66	Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. <i>Shock</i> , 2007 , 27, 482-7	3.4	24
65	Rational approach in the management of Pseudomonas aeruginosa infections. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 578-586	5.4	24
64	Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. <i>Journal of Virology</i> , 2015 , 89, 970-88	6.6	23
63	Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. <i>PLoS ONE</i> , 2013 , 8, e74831	3.7	22
62	Coxiella burnetii vascular graft infection. <i>BMC Infectious Diseases</i> , 2005 , 5, 109	4	22
61	Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. <i>Frontiers in Immunology</i> , 2017 , 8, 26	8.4	21
60	Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. <i>PLoS ONE</i> , 2012 , 7, e35485	3.7	21
59	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021 , 72, S121-S127	11.6	21
58	Invasive mould infections: a multi-disciplinary update. <i>Medical Mycology</i> , 2009 , 47, 571-83	3.9	19
57	The need for aminoglycosides in combination with ßactams for high-risk, febrile neutropaenic patients with leukaemia. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 13-22	1.6	19
56	The role of macrophage migration inhibitory factor in mouse islet transplantation. <i>Transplantation</i> , 2008 , 86, 1361-9	1.8	18
55	Prognostic value of quickSOFA as a predictor of 28-day mortality among febrile adult patients presenting to emergency departments in Dar es Salaam, Tanzania. <i>PLoS ONE</i> , 2018 , 13, e0197982	3.7	17
54	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. <i>Cytokine</i> , 2012 , 60, 338-40	4	17
53	Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. <i>Journal of Mass Spectrometry</i> , 2007 , 42, 440-9	2.2	17
52	LetB add invasive aspergillosis to the list of influenza complications. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 733-735	35.1	16

51	Role of MyD88 and Toll-like receptors 2 and 4 in the sensing of Parachlamydia acanthamoebae. <i>Infection and Immunity</i> , 2010 , 78, 5195-201	3.7	16
50	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. <i>Haematologica</i> , 2018 , 103, e527-e530	6.6	15
49	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa075	1	14
48	IRF5 Is a Key Regulator of Macrophage Response to Lipopolysaccharide in Newborns. <i>Frontiers in Immunology</i> , 2018 , 9, 1597	8.4	14
47	Polymorphisms in tumor necrosis factor- β increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*. <i>Critical Care Medicine</i> , 2014 , 42, e304-8	1.4	14
46	Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis. <i>PLoS Neglected Tropical Diseases</i> , 2010 , 4, e605	4.8	14
45	Initial antimicrobial management of sepsis. <i>Critical Care</i> , 2021 , 25, 307	10.8	14
44	Monocyte deactivation in septic shock. <i>Current Opinion in Infectious Diseases</i> , 1998 , 11, 279-83	5.4	13
43	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. <i>Nature Communications</i> , 2021 , 12, 4888	17.4	13
42	Histoplasma capsulatum var. duboisii infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 85-9	2.9	12
41	Candida arteritis in patients who have not received organ transplants: case report and review of the literature. <i>Clinical Infectious Diseases</i> , 2008 , 46, e106-11	11.6	12
40	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. <i>Clinical Immunology</i> , 2007 , 123, 60-5	9	12
39	Cytokines in septic shock. <i>Current Clinical Topics in Infectious Diseases</i> , 2002 , 22, 1-23		12
38	An Early Warning Score to predict ICU admission in COVID-19 positive patients. <i>Journal of Infection</i> , 2020 , 81, 816-846	18.9	11
37	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34, 386-8	14.3	11
36	Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis. <i>PLoS ONE</i> , 2016 , 11, e0163542	3.7	11
35	Emerging single-cell technologies in immunology. <i>Journal of Leukocyte Biology</i> , 2015 , 98, 23-32	6.5	9
34	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. <i>Journal of Infection</i> , 2018 , 76, 489-495	18.9	8

33	Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins. <i>Journal of Virology</i> , 2015 , 89, 3819-32	6.6	8
32	TLR2-mediated neutrophil depletion exacerbates bacterial sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 6889-90	11.5	8
31	Macrophage migration inhibitory factor promotes the migration of dendritic cells through CD74 and the activation of the Src/PI3K/myosin II pathway. <i>FASEB Journal</i> , 2021 , 35, e21418	0.9	8
30	Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease. <i>Psychosomatic Medicine</i> , 2007 , 69, 68-73	3.7	7
29	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). <i>British Journal of Haematology</i> , 2000 , 109, 396-404	4.5	7
28	Invasive Candida infections in the ICU. <i>Mycoses</i> , 2012 , 55, 65-72	5.2	6
27	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 665-7	5.1	6
26	Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?. <i>Current Opinion in Critical Care</i> , 2010 , 16, 442-4	3.5	6
25	What's new in antimicrobial use and resistance in critically ill patients?. <i>Intensive Care Medicine</i> , 2014 , 40, 422-6	14.5	5
24	Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock. <i>Journal of Infection</i> , 2021 , 82, 125-134	18.9	5
23	A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , 2009 , 49, 733-5	11.6	4
22	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab471	1	4
21	Plant Immune Responses: Aphids Strike Back. <i>Current Biology</i> , 2015 , 25, R604-6	6.3	3
20	Modulation of human memory T-cell function by different antigen-presenting cells. <i>European Journal of Immunology</i> , 2012 , 42, 799-802	6.1	3
19	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021 , 11, e049232	3	3
18	Cytokines and Escherichia coli Sepsis. <i>EcoSal Plus</i> , 2006 , 2,	7.7	2
17	The Generation of Inflammatory Responses 2002 , 687-727		2
16	Macrophage Migration Inhibitory Factor (MIF): A Pro-Inflammatory Mediator of Sepsis. <i>Perspectives on Critical Care Infectious Diseases</i> , 2001 , 45-67		2

15	Host Innate Immune Responses to Microbial Pathogens. <i>Current Vascular Pharmacology</i> , 2013 , 11, 123-133		1
14	Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock 2002 , 539-558		1
13	High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure.. <i>Intensive Care Medicine Experimental</i> , 2022 , 10, 5	3.7	1
12	Macrophage Migration Inhibitory Factor (MIF)		1
11	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. <i>Mycoses</i> , 2021 , 64, 1512-1520	5.2	1
10	Infections in the Cancer Patient 2017 , 723-738.e3		0
9	Clinical expert round table discussion (session 1) at the Margaux Conference on Critical Illness: innate immunity: host recognition of and sensitivity to bacterial components. <i>Critical Care Medicine</i> , 2001 , 29, S19-20	1.4	0
8	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. <i>Studies in Health Technology and Informatics</i> , 2020 , 270, 1163-1167	0.5	0
7	Antimicrobial Therapy 2018 , 185-199		
6	Epigenetic Control of MIF Expression 2012 , 121-137		
5	Reply to Pasqualotto and Sukiennik. <i>Clinical Infectious Diseases</i> , 2008 , 47, 293-294		11.6
4	MIF in Innate Immunity and Infectious Diseases 2007 , 107-132		
3	Response to van Saene et al. comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients". <i>Intensive Care Medicine</i> , 2003 , 29, 1196		14.5
2	Gas6 and Its Receptors Are Implicated in Sepsis as Modulators of Innate Immunity.. <i>Blood</i> , 2007 , 110, 2409-2409		2.2
1	Infections in the neutropenic cancer patient 2010 , 804-820		